A recent proposal by the Brazilian government to effectively privatize its patent office has alarmed patient advocates, who fear such a move would make it easier for the pharmaceutical industry to maintain monopolies on medicines and, consequently, higher prices in one of the world’s largest economies.

In its notice, the Ministry of Economy suggested merging the National Institute of Industrial Property, or INPI, which oversees patent reviews, with another government agency to form a new public-private sector entity called the Brazilian Agency for Development and Industrial Property, or ABDPI. The goal is to create “greater efficiencies,” according to the ministry notice.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy